DDW

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
Freitag, Mai 10, 2024
Assistant professor, AFL, Research, Cleveland Clinic, Serum, Coeliac disease, Psychiatry, Multiple sclerosis, Communication, DDW, SIRT6, Annual general meeting, CMSC, Biotechnology, Pharmaceutical industry

NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, May 6, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 12-14 and 21-22: Bio€quity Europe 2024.
  • Jessica Breu, Vice President Investor Relations and Communications at Immunic, will attend and host one-on-one investor meetings at this conference taking place in San Sebastián, Spain and virtually.
  • To schedule a meeting, please use the Bio€quity conference portal or contact Jessica Breu at: [email protected] .
  • Presentation Title: Impact of Vidofludimus Calcium (VidoCa) on Serum Neurofilament Light Chain (NfL) Levels in Patients with Progressive Multiple Sclerosis: Interim Data from the CALLIPER Trial

EQS-News: Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Retrieved on: 
Freitag, Mai 10, 2024
Mortality, Cancer, Colorectal cancer, Gastroenterology, Gastrointestinal disease, Machine learning, Conditional sentence, CRC, Trial of the century, Artificial intelligence, DNA, Incidence, Patient, Endoscopy, Fecal immunochemical test, FIT, DDW, Messenger, Biomarker, AA, Medical imaging

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Key Points: 
  • Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
  • Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
    BERKELEY, US – MAINZ, Germany – May 7, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present  an analysis from  its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21st.
  • eAArly DETECT is a US multi-site study performed at 21 specialized gastroenterology sites that enrolled 254 clinical patients .
  • By leveraging this dual approach, Mainz Biomed aims to accelerate the shift from cancer detection to prevention by advancing current colorectal cancer screening practices, reflecting its commitment to reducing cancer mortality rates worldwide.

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Transfer, FDA, Research, Inflammation, Cell cycle, IND, CNS, Prostate cancer, AACR, Cancer, Autoimmunity, Lung cancer, Traffic barrier, MGD, Food, European Alliance, Conference, Roche, DDW, Pericarditis, Therapy, NSCLC, Rat, Ulcerative colitis, Poster, NLRP3, CCNE1, SCLC, Finance, Triple-negative breast cancer, Consultant, Public expenditure, Obesity, Gout, GLP, DSM-IV codes, Clinical trial, Toxicology, CDK2, G&A, Investigational New Drug, MYC, Research and development, EULAR, Carcinoma, Administration, Rheumatoid arthritis, Neoplasm, POC, Dermatology, Growth, Pharmaceutical industry

“We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • “We’re excited by the significant advances made across our entire portfolio, including both our oncology and immunology/inflammation programs,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • The Company is on track to determine the recommended Phase 2 dose (RP2D) in Q2 2024 and report Phase 1 study results in H2 2024.
  • Announce the recommended Phase 2 dose for the MRT-2359 Phase 1/2 study in Q2 2024 and report Phase 1 clinical results in H2 2024.
  • Net Loss: Net loss for the first quarter of 2024 was $32.0 million, compared to $33.3 million for the fourth quarter of 2023.

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Vonoprazan/amoxicillin, Table, FDA, DTC, Pharmacy, Gastrointestinal disease, NERD, NDA, Hercules, Amazon Prime Video, Food, Research, Webcast, Business, Forecasting, Prescription, Cigna, PPI, PDUFA, Tablet, Patient, Physician, Ratio, Enzyme inhibitor, DDW, Marketing, Vonoprazan/amoxicillin/clarithromycin, Heartburn, Hulu, GERD, Clinical trial, GAAP, Growth, Overalls, Eosinophilic esophagitis, Pharmaceutical industry

ET

Key Points: 
  • ET
    FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
  • Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

Retrieved on: 
Donnerstag, Mai 9, 2024
DDW, Abstract (summary), American Gastroenterological Association, Gastrointestinal disease, SAN

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.

Key Points: 
  • SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
  • Details of the presentations are as follows:
    Abstracts selected by the American Gastroenterological Association (AGA) for presentation at DDW will be available in a supplement to Gastroenterology.
  • The presentations and information about DDW 2024 may be accessed at https://ddw.org/ .

Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

Retrieved on: 
Donnerstag, Mai 9, 2024
Bezafibrate, Gastrointestinal disease, Learning, Intercept, Abstract, Aspartic acid, Primary biliary cholangitis, Fibrosis, Intercept Pharmaceuticals, Therapy, Senior, Liver, Obeticholic acid, DDW, Hepatology, PBC, Risk, Head, Pharmaceutical industry

MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024.

Key Points: 
  • MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024.
  • “These data, along with new analyses from our landmark Phase 3 POISE trial, showcase our continued commitment to helping improve the lives of people living with PBC.
  • A full list of sessions at DDW 2024 is available at www.ddw.org .
  • Attendees of DDW can visit Intercept at booths #3741 and #3828 throughout the meeting.

Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference

Retrieved on: 
Dienstag, Mai 7, 2024
Patient, D.C, Safety, Food, MD, Conference, Irritable bowel syndrome, Constipation, IBS-C, DDW, Pharmaceutical industry

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.

Key Points: 
  • WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
  • Title: Comparing the Efficacy of Tenapanor in Irritable Bowel Syndrome with Constipation in Hispanic vs Non-Hispanic Patients: A Posthoc Analysis of Patients in the Phase 3 T3MPO-1 and T3MPO-2 Studies
    In addition to the poster presentations during DDW, Ardelyx is sponsoring a Product Theater titled: “Discover IBSRELA: a Different Mechanism of Action to Treat Adults With IBS-C: A Case-Based Discussion,” on May 19, 2024, from 2:30-3:15 PM EDT, where Brooks Cash, MD, will lead an engaging discussion about important clinical considerations for managing IBS-C in adult patients.
  • The presentation will include interactive patient case studies, along with IBSRELA efficacy and safety data from the Phase 3 clinical trial program.

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Retrieved on: 
Dienstag, Mai 7, 2024
Mortality, Cancer, Gastroenterology, Colorectal cancer, Machine learning, Conditional sentence, CRC, Trial of the century, Artificial intelligence, DNA, Incidence, Patient, Endoscopy, Fecal immunochemical test, FIT, DDW, Messenger, Biomarker, AA, Medical imaging

BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21st.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May 18th to May 21st.
  • DDW is recognized as a premier forum for the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
  • eAArly DETECT is a US multi-site study performed at 21 specialized gastroenterology sites that enrolled 254 clinical patients.
  • By leveraging this dual approach, Mainz Biomed aims to accelerate the shift from cancer detection to prevention by advancing current colorectal cancer screening practices, reflecting its commitment to reducing cancer mortality rates worldwide.

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

Retrieved on: 
Montag, Mai 6, 2024
DDW, Abstract (summary), Serri, Sardinia, American Gastroenterological Association

Abstracts selected by the American Gastroenterological Association (AGA) for presentation at DDW will be available in a supplement to Gastroenterology.

Key Points: 
  • Abstracts selected by the American Gastroenterological Association (AGA) for presentation at DDW will be available in a supplement to Gastroenterology.
  • All information presented at DDW, including poster presentations, is embargoed until 12:01 AM Eastern on the day of the presentation.
  • The poster presentation will be made available on the Biora Therapeutics website following the meeting.

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PS, Phase, Capsule, The Lancet, Gastrointestinal disease, Safety, AbbVie, Food, Interstitial cystitis, SBS, Depreciation, Interest, Trial of the century, Endometriosis, Research, Hepatology, IQVIA, Disease, Autoimmune disease, Patient, Liver, Acquisition, Short bowel syndrome, Constipation, DDW, STARS, Primary biliary cholangitis, Bank statement, Adjustment, Standard of care, Clinical trial, PBC, GAAP, Food and Drug Administration, Income tax, Ageing, Pharmaceutical industry

LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.

Key Points: 
  • LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.
  • Total revenue in the first quarter of 2024 was $74.9 million, compared to $104.1 million in the first quarter of 2023.
  • Operating expenses in the first quarter of 2024 were $63.9 million, compared to $44.0 million in the first quarter of 2023.
  • Ironwood generated $45.0 million in cash from operations in the first quarter of 2024, compared to $80.2 million in cash from operations in the first quarter of 2023.